Atlas company financials

UNITED THERAPEUTICS Corp

Standardized 18-year financial series for UNITED THERAPEUTICS Corp, built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001082554FY2008 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$3.2B

Adjusted EBITDA

—

Net result

$1.3B

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$799.5M

TTM revenue

$3.1B

TTM free cash flow

—

Latest quarter net result

$338.7M

Quarterly coverage: 50 periods · latest quarter FY2025-Q3 · TTM revenue growth 20.9%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · united-therapeutics-corp-fy2008 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-02-24 · Retrieved: 2026-04-26T11:43:21.109212+00:00
SEC EDGAR companyfacts
us-gaap:GrossProfit · us gaap companyfacts · comparative · united-therapeutics-corp-fy2009 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-02-28 · Retrieved: 2026-04-26T11:43:21.109212+00:00
SEC EDGAR companyfacts
primary · united-therapeutics-corp-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-02-26 · Retrieved: 2026-04-26T11:43:21.109212+00:00
SEC EDGAR companyfacts
primary · united-therapeutics-corp-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-02-25 · Retrieved: 2026-04-26T11:43:21.109212+00:00
SEC EDGAR companyfacts
primary · united-therapeutics-corp-fy2014 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2015-02-24 · Retrieved: 2026-04-26T11:43:21.109212+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2008	281M	—	-82M	—	-40M	-124M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing current assets · missing current liabilities · missing gross profit · missing inventory · missing net financial debt · missing net result · missing total assets
FY2009	370M	—	26M	—	100M	-95M	—	comparative annual fact carried from later 10k · missing adjusted ebitda · missing net financial debt · missing net result
FY2010	604M	—	164M	—	212M	-19M	—	missing adjusted ebitda · missing net financial debt · missing net result
FY2011	743M	—	318M	—	250M	-36M	—	missing adjusted ebitda · missing net financial debt · missing net result
FY2012	916M	—	422M	—	324M	-112M	-153M	missing adjusted ebitda · missing net result
FY2013	1B	—	292M	—	425M	-32M	-212M	missing adjusted ebitda · missing net result
FY2014	1B	—	539M	—	355M	-47M	-398M	missing adjusted ebitda · missing net result
FY2015	1B	—	699M	—	383M	-50M	—	missing adjusted ebitda · missing gross profit · missing net financial debt · missing net result
FY2016	2B	—	1B	—	644M	-38M	—

Filing provenance